Brooklyn Gross Margin Trend from 2010 to 2022

BTX
 Stock
  

USD 0.57  0.03  5.00%   

Brooklyn Immunotherapeuti Gross Margin yearly trend continues to be fairly stable with very little volatility. Gross Margin is likely to outpace its year average in 2022. During the period from 2010 to 2022, Brooklyn Immunotherapeuti Gross Margin regression line of anual values had r-squared of 0.39 and arithmetic mean of  0.64. Brooklyn Immunotherapeuti Direct Expenses is fairly stable at the moment as compared to the past year. Brooklyn Immunotherapeuti reported Direct Expenses of 442,750 in 2021. Cost of Revenue is likely to rise to about 9.2 M in 2022, whereas Consolidated Income is likely to drop (125.5 M) in 2022.
  
Refresh
Check Brooklyn Immunotherapeuti financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Brooklyn main balance sheet or income statement drivers, such as Direct Expenses of 541.5 K, Cost of Revenue of 9.2 M or Gross Profit of 12.2 M, as well as many exotic indicators such as Long Term Debt to Equity of 3.0E-4, PPandE Turnover of 1.03 or Receivables Turnover of 11.02. Brooklyn financial statements analysis is a perfect complement when working with Brooklyn Immunotherapeuti Valuation or Volatility modules. It can also supplement various Brooklyn Immunotherapeuti Technical models. Continue to the analysis of Brooklyn Immunotherapeuti Correlation against competitors.

Brooklyn Immunotherapeuti Quarterly Gross Margin

0.432

Share

Brooklyn Gross Margin Breakdown

Showing smoothed Gross Margin of Brooklyn Immunotherapeutics with missing and latest data points interpolated. Gross Margin measures the ratio between a company's Gross Profit and Revenues.Brooklyn Immunotherapeuti's Gross Margin historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Brooklyn Immunotherapeuti's overall financial position and show how it may be relating to other accounts over time.
Gross Margin10 Years Trend
Decreasing
Slightly volatile
 Gross Margin 
Share
      Timeline 

Brooklyn Gross Margin Regression Statistics

Arithmetic Mean 0.64
Geometric Mean 0.64
Coefficient Of Variation 12.84
Mean Deviation 0.07
Median 0.65
Standard Deviation 0.08
Sample Variance 0.006813
Range 0.27
R-Value(0.62)
Mean Square Error 0.004537
R-Squared 0.39
Significance 0.022613
Slope(0.013228)
Total Sum of Squares 0.08

Brooklyn Gross Margin History

2012 0.74
2013 0.68
2014 0.57
2015 0.49
2016 0.65
2019 0.62
2021 0.56

About Brooklyn Immunotherapeuti Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Brooklyn Immunotherapeuti income statement, its balance sheet, and the statement of cash flows. Brooklyn Immunotherapeuti investors use historical funamental indicators, such as Brooklyn Immunotherapeuti's Gross Margin, to determine how well the company is positioned to perform in the future. Although Brooklyn Immunotherapeuti investors may use each financial statement separately, they are all related. The changes in Brooklyn Immunotherapeuti's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Brooklyn Immunotherapeuti's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Brooklyn Immunotherapeuti Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Brooklyn Immunotherapeuti. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for 2022
Gross Margin 0.56  0.57 
Brooklyn ImmunoTherapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing therapies to treat patients with cancer. Brooklyn ImmunoTherapeutics, Inc. is based in Brooklyn, New York. Brooklyn Immunotherapeuti operates under Biotechnology classification in the United States and is traded on NYSEMKT Exchange. It employs 10 people.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Brooklyn Immunotherapeuti without increasing your portfolio risk or giving up expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate.risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Pair Correlation Now

   

Pair Correlation

Compare performance and examine fundamental relationship between any two equity instruments
All  Next Launch Module
Continue to the analysis of Brooklyn Immunotherapeuti Correlation against competitors. Note that the Brooklyn Immunotherapeuti information on this page should be used as a complementary analysis to other Brooklyn Immunotherapeuti's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Focused Opportunities module to build portfolios using our predefined set of ideas and optimize them against your investing preferences.

Complementary Tools for Brooklyn Stock analysis

When running Brooklyn Immunotherapeuti price analysis, check to measure Brooklyn Immunotherapeuti's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Brooklyn Immunotherapeuti is operating at the current time. Most of Brooklyn Immunotherapeuti's value examination focuses on studying past and present price action to predict the probability of Brooklyn Immunotherapeuti's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Brooklyn Immunotherapeuti's price. Additionally, you may evaluate how the addition of Brooklyn Immunotherapeuti to your portfolios can decrease your overall portfolio volatility.
ETF Directory
Find actively traded Exchange Traded Funds (ETF) from around the world
Go
Fund Screener
Find actively-traded funds from around the world traded on over 30 global exchanges
Go
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Go
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Go
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Go
Price Transformation
Use Price Transformation models to analyze depth of different equity instruments across global markets
Go
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
Go
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Go
CEO Directory
Screen CEOs from public companies around the world
Go
Is Brooklyn Immunotherapeuti's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Brooklyn Immunotherapeuti. If investors know Brooklyn will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Brooklyn Immunotherapeuti listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
33 M
Return On Assets
-0.74
Return On Equity
-156.16
The market value of Brooklyn Immunotherapeuti is measured differently than its book value, which is the value of Brooklyn that is recorded on the company's balance sheet. Investors also form their own opinion of Brooklyn Immunotherapeuti's value that differs from its market value or its book value, called intrinsic value, which is Brooklyn Immunotherapeuti's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Brooklyn Immunotherapeuti's market value can be influenced by many factors that don't directly affect Brooklyn Immunotherapeuti's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Brooklyn Immunotherapeuti's value and its price as these two are different measures arrived at by different means. Investors typically determine Brooklyn Immunotherapeuti value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Brooklyn Immunotherapeuti's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.